Full Text View
Tabular View
No Study Results Posted
Related Studies
Intraoperative Cell Saver Autotransfusion Use for Major Surgical Oncology Operations. (Cellsaver)
This study has been completed.

First Received on June 27, 2008.   Last Updated on January 12, 2010   History of Changes
Sponsor: University of Louisville
Information provided by: University of Louisville
ClinicalTrials.gov Identifier: NCT00708513
  Purpose

The purpose of this study is to demonstrate the safety and benefit of auto-transfusion filtered blood in patients undergoing major surgical oncology procedures.


Condition
Pancreaticoduodenectomy
Pancreatectomy
Esophagectomy
Gastrectomy
Hepatectomy

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Phase I/II Evaluation of Intraoperative Autotransfusion Filtration for Major Surgical Oncology Operations

Resource links provided by NLM:


Further study details as provided by University of Louisville:

Estimated Enrollment: 90
Study Start Date: December 2003
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Detailed Description:

Homologous blood transfusions during surgical procedures are becoming more challenging, due to lack of adequate reserves and the significant risks of transfusion reactions. Recent advances in the use of patient's own blood (autologous transfusion) has rapidly gained acceptance in major surgical procedures, however due to the requirement for prior planning and the expense of obtaining and storing a patient's blood prior to surgery this alternative is less than ideal.

This research study utilizes a third alternative, a technique called intraoperative autotransfusion, which successfully salvages a patient's blood during surgery and reinfuses the blood back into the patient. The blood salvaging device uses a filtration device that successfully filters out all tumor cells to prevent re-infusion of viable cancer cells.

This study is designed to demonstrate the safety and benefits of the blood salvaging device on patients undergoing major surgical oncology procedures.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Surgical Oncology Clinic

Criteria

Inclusion Criteria:

  1. Subject is undergoing a major surgical oncology procedure and has potential for extensive blood loss.
  2. Subject is ≥ 18 years of age.
  3. Subject or Subject's Legally Authorized Representative (LAR) has signed an IRB-approved informed consent form.

Exclusion Criteria:

  1. Subject has medical, social, or psychological factors that, in the opinion of the Investigator, could impact safety or compliance with study procedures.
  2. Subject is < 18 years of age.
  3. Subject or Subject's LAR did not sign IRB-approved informed consent form.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00708513

Locations
United States, Kentucky
Norton Healthcare
Louisville, Kentucky, United States, 40202
University of Louisville Hospital
Louisville, Kentucky, United States, 40202
Sponsors and Collaborators
University of Louisville
Investigators
Principal Investigator: Robert CG Martin, MD University of Louisville
  More Information

No publications provided

Responsible Party: Robert C. G. Martin, University of Louisville
ClinicalTrials.gov Identifier: NCT00708513     History of Changes
Other Study ID Numbers: Cell Saver 704.03
Study First Received: June 27, 2008
Last Updated: January 12, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by University of Louisville:
Cell Saver
Liver Tumors
Liver Cancer
Surgical Oncology
Whipple
Blood Transfusion
Blood salvage
cancer surgery
blood loss
blood transfusion

ClinicalTrials.gov processed this record on February 12, 2012